Dr Seiler explained, “We do tend to see clusters of bladder cancer in some families, but it can be difficult to discern if these are due to shared risk factors, such as environmental exposures or lifestyle choices (i.e. tobacco use), or if these are due to germline mutations within the family.”
Importantly, there are currently no guidelines about when to refer younger patients with bladder cancer to genetic counselling. Other malignancies, however, have tackled this unmet need [1], and Dr Seiler pointed out that for the time being we should adopt similar practices. In short, if a patient is <50 years of age, or if they have >3 cases of breast, ovarian, pancreatic, or prostate cancer in close relatives (per definition parents, siblings, or children), it is reasonable to offer genetic counselling.
There is scant data examining germline mutations in bladder cancer to date; one recent study sequenced a selected cancer-related gene panel in 98 bladder cancer patients [2]. Although the authors concluded that germline mutations within this cohort were related to DNA repair, this study was not genome-wide, and was inherently biased because the selected gene panel featured many genes involved in DNA repair.
Analysing the Cancer Genome Atlas Program, a few known somatic differences between older and younger patients with urothelial carcinoma have been identified. For example, inactivating mutations in canonical tumour suppressor genes RB1 and TP53 are associated with younger patients, as well as higher neoantigen loads, and higher interferon-gamma signalling and chemokine signalling. Of the known molecular subtypes of urothelial carcinoma, the luminal papillary subtype appears to be more prevalent in younger patients. Interestingly, this luminal papillary subtype has characteristically low levels of immune infiltrate that make it potentially less likely to show a favourable response to checkpoint inhibition treatment. In exciting complementary data, transcriptome profiling of 368 tumour samples from patients in the IMvigor 210 trials with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab trial revealed that the TP53 and/or RB1 mutated samples in neuronal tumours of the Lund subtype classification was associated with the best response [3].
In a video interview, Prof. Morgan Rouprêt (Pierre and Marie Curie University, France) and Prof. Fiona Burkhard (Inselspital University Hospital of Bern, Switzerland) gave insights from the plenary session at EAU19 looking at bladder cancer in the young patient and why is it important to focus on these patients [4].
- Shuch et al. J Clin Oncol. 2014 Feb 10;32(5):431-7.
- Na et al. BJU Int 2018 Nov;122(5):808-813.
- Kim et al. Eur Urol. 2019 Mar 6. pii: S0302-2838(19)30160-5.
- https://www.youtube.com/watch?v=wgGKVB_-7cA&list=PLCVO1Vai8uzXJOGRwfLw5uDBghBvjcfKe&index=8&t=0s
Posted on
Previous Article
« Radioguided surgery is the future? Next Article
Surgery of the axilla: indications decrease »
« Radioguided surgery is the future? Next Article
Surgery of the axilla: indications decrease »
Table of Contents: EAU 2019
Featured articles
Prostate Cancer
Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
Radioguided surgery is the future?
Bladder Cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Robot-assisted radical cystectomy or open radical cystectomy?
Renal Transplantation and Renal Cell Carcinoma
Andrology
Microdissection testicular sperm extraction (microTESE)
Male infertility/Premature ejaculation
Testosterone replacement therapy: Safe and maybe even protective
Focus on treatment of erectile dysfunction and Peyronie’s disease
Penile prosthesis implantation
Functional Urology
Decision aids are too difficult for patients
Lower Urinary Tract Symptoms
The Urodynamics for Prostate Surgery Trial
Minimally invasive surgical techniques must compete against pharmacotherapy in benign prostate hyperplasia (BPH)
Related Articles
August 31, 2021
Worse renal function after radical versus partial nephrectomy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy